ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,870.62
      -1.32%
      US Tech 100
      19,877.20
      -2.31%
      Dow Jones
      43,444.99
      -0.70%
      Brent Oil
      70.895
      0.00%
      Bitcoin
      91,040.85
      -0.02%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Assertio Holdings Inc (ASRT) Quote

      Assertio Holdings Inc

      Assertio Holdings Inc (ASRT)

      BNP Paribas Asset Management Luxembourg
      0.8114
      -0.0305
      (-3.62%)
      Closed November 15 4:00PM
      Delayed by 15 minutes
      0.8317
      0.0203
      (2.50%)
      After Hours: 6:51PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      0.8317
      Bid
      0.82
      Ask
      0.8317
      Volume
      1,027,245
      0.78 Day's Range 0.8385
      0.7324 52 Week Range 1.798
      Market Cap
      79.291M
      Previous Close
      0.8419
      Open
      0.8312
      Last Trade
      1
      @
      0.8316
      Last Trade Time
      Financial Volume
      $ 822,226
      VWAP
      0.800419
      Average Volume (3m)
      550,761
      Shares Outstanding
      95,335,629
      Dividend Yield
      -
      PE Ratio
      -0.23
      Earnings Per Share (EPS)
      -3.48
      Revenue
      152.07M
      Net Profit
      -331.94M

      About Assertio Holdings Inc

      Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management... Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.assertiotx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Assertio Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ASRT. The last closing price for Assertio was $0.84. Over the last year, Assertio shares have traded in a share price range of $ 0.7324 to $ 1.798.

      Assertio currently has 95,335,629 shares outstanding. The market capitalization of Assertio is $80.26 million. Assertio has a price to earnings ratio (PE ratio) of -0.23.

      Ask ADVFN Intelligence (AI)

      ASRT Latest News

      More News

      Form 8-K - Current report

      November 12 2024
      Edgar (US Regulatory)

      Assertio Reports Third Quarter 2024 Financial Results

      Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE...

      November 11 2024
      GlobeNewswire Inc.

      Assertio Provides Response to Letter from Short-seller

      Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company...

      November 11 2024
      GlobeNewswire Inc.

      Tesla Rises 5% Pre-Market After Surpassing $1T Market Value; U.S. Bans TSMC From Selling Advanced Chips to China

      Tesla (NASDAQ:TSLA) – On Friday, Tesla’s market capitalization surpassed $1 trillion following Donald Trump’s election, anticipated to support CEO Elon Musk’s business ventures, as he...

      November 11 2024
      IH Market News

      Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024

      LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

      October 30 2024
      GlobeNewswire Inc.

      Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

      LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

      October 11 2024
      GlobeNewswire Inc.

      Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

      October 04 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      October 03 2024
      Edgar (US Regulatory)

      Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

      LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

      September 03 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 07 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.1683-16.8311.02990.79519152490.8685768CS
      4-0.3283-28.30172413791.161.160.7958026070.94068977CS
      12-0.4283-33.99206349211.261.380.7955507611.07204685CS
      26-0.1783-17.65346534651.011.7980.7958391821.22377675CS
      52-0.2383-22.27102803741.071.7980.73249660301.09691268CS
      156-0.8083-49.28658536591.648.010.732412743483.20044382CS
      2600.05587.19164840830.77598.010.3322844001.65139366CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.17B
      CYCNCyclerion Therapeutics Inc
      $ 2.5306
      (42.97%)
      		11.98M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		165.57M
      PULMPulmatrix Inc
      $ 6.5586
      (39.54%)
      		5.36M
      ZTEKZentek Ltd
      $ 1.2574
      (29.96%)
      		308.31k
      TFFPTFF Pharmaceuticals Inc
      $ 0.376101
      (-76.49%)
      		9.15M
      EYENEyenovia Inc
      $ 0.10185
      (-70.05%)
      		51.77M
      CTXRCitius Pharmaceuticals Inc
      $ 0.1974
      (-39.89%)
      		11.02M
      VVPRVivoPower International PLC
      $ 0.8151
      (-39.62%)
      		2.28M
      IPWiPower Inc
      $ 0.7302
      (-39.15%)
      		1.13M
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.15B
      ELABElevai Labs Inc
      $ 0.0211
      (-19.47%)
      		372.92M
      NVDANVIDIA Corporation
      $ 141.98
      (-3.26%)
      		243.27M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		164.37M
      STISolidion Technology Inc
      $ 0.44
      (25.71%)
      		139.23M

      ASRT Discussion

      View Posts
      dcaf7 dcaf7 2 days ago
      Same day dosing data will be presented at SABCS meeting by Lee Schwartzberg on December 13, 2024.
      Abstract title is "Eflapegrastim, a long-acting GCSF, administered the same day as chemotherapy in patients with early-stage breast cancer: Results from a multicenter, open-label, study". Full abstract release date is November 25, 2024.
      👍️0
      dcaf7 dcaf7 4 days ago
      On earning call, they said that SPRIX might become an important asset due to NONPAIN act.
      The NOPAIN Act expands patient and provider access to FDA-approved non-opioids in all outpatient surgical settings beginning in 2025 by providing separate Medicare reimbursement for non-opioid therapies.
      👍️0
      dcaf7 dcaf7 4 months ago
      H.C. Wainwright starts Assertio at buy.
      The investment bank said it believes Rolvedon could reach peak annual sales of around $140M in the early 2030s. It added that “long run positive traction” from products such as Rolvedon, Otrexup and Sympazan “ought to drive renewed interest from investors.”
      The bank set its price target at $4.
      👍️ 1
      glenn1919 glenn1919 4 months ago
      ASRT.......................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 5 months ago
      ASRT................................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
      👍️0
      ATLcitizen ATLcitizen 5 months ago
      Heather Mason recently purchased 25K of ASRT shares.
      👍️ 1
      dcaf7 dcaf7 5 months ago
      A meta-analysis of the effect of pegfilgrastim biosimilars and eflapegrastim on DSN was presented at ASCO. "Additionally, eflapegrastim, another long-acting granulocyte-colony stimulating factor agent, significantly reduced DSN compared to conventional pegfilgrastim (WMD, n = –0.13 days; 95% CI –0.24 to –0.03; P = .01). The researchers recommended “exploring the impact of the drug in clinical settings on costs and patient-reported outcomes could provide valuable insights into optimizing the management of chemotherapy-related neutropenia.”
      https://www.centerforbiosimilars.com/view/asco-2024-posters-showcase-positive-data-on-denosumab-pegfilgrastim-biosimilars
      👍️ 1
      Propain Propain 6 months ago
      bought some shares today. Gaurantee the stock will tumble now!
      👍️0
      dcaf7 dcaf7 6 months ago
      Rolvedon/eflapegrastim is a new molecule. You cannot call it "novel formulation". Novel formulation of what? Neulasta? Nonsense.
      👍️ 1
      ATLcitizen ATLcitizen 6 months ago
      dcaf7, please elaborate on what you mean?
      👍️0
      dcaf7 dcaf7 6 months ago
      Listened to yesterday ASRT presentation. They call Rolvedon a "novel formulation" (slide 5). Looks like these guys don't know what Rolvedon really is.
      👍️ 1
      dcaf7 dcaf7 8 months ago
      Rolvedon pediatric study is a postmarketing requirement from FDA. If it was up to Spectrum, they wouldn’t run it because of small commercial opportunity and approved Neulasta. I think completion of Phase 2 is what ASRT needs to accomplish. I doubt phase 3 will be required but they need to complete current study and to show the results to FDA that can happen 3-4 years away from now. As for Neulasta you can find that “no overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance”. As for same day dosing, I think, nobody knows what the next step looks like. Depends on data. Three years ago, JT said “If data is good, we would engage in a discussion with the FDA to path forward”. About a year ago, TR said the same, “whether that be going to chat with FDA about a regulatory path forward, whether it is publication, it is really contingent upon what we see in that data”.
      👍️ 1
      ATLcitizen ATLcitizen 8 months ago
      A couple questions. A few days ago, a phase 2 study showed pediatric patients tolerated Rolvedon without requiring dose reduction. I could not copy link, but can find on Stocktwits ASRT from poster Avedesian. What is the significance? Does this mean Assertio may market to pediatric patients now, or phase 3 required? Also, this poster says that Neulasta and biosimilars required dose reduction for pediatric patients. Does this mean R is safer? How does this differentiate R from Neulasta and biosimilars? Next question: Hanmi recently said in interview with a Korean biopharma news that they expect R to be successful in their same day dosing trial to get a 'competitive edge'. IMO this appears to be a sign that they will continue with another study if the current study is successful. Another poster on X, claiming to be a doctor (this was copied on Stocktwits) said that they expect it to be short study due to requiring only one cycle of treatment. Any ideas of how long to complete another study, including enrollment? Should this be a quicker study? TIA!
      👍️0
      glenn1919 glenn1919 8 months ago
      ASRT.........................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 8 months ago
      ASRT 10Q due March 11
      👍️0
      dcaf7 dcaf7 8 months ago
      I don’t have an answer about what does it mean. I can explain why they will finish it earlier. Because they reduced the number of patients from 90 to 50. Good sign is that trial is still enrolling. It means they think that a positive outcome is still possible. What is next if the data is good? In my opinion, for approval they need to conduct a larger trial. Not sure if they want it.
      👍️ 1
      ATLcitizen ATLcitizen 8 months ago
      The same day dosing trial for R has moved forward its study completion date from june 2025 to july 2024. Thoughts? Is this a good sign and if successful, what is next?
      👍️0
      dcaf7 dcaf7 9 months ago
      Hanmi Pharma said it has signed a strategic agreement with its U.S. partner company, Assertio Holdings, which previously acquired Spectrum Pharmaceuticals, to re-acquire the rights to Rolontis, a long-acting neutropenia treatment and Korea's 33rd novel drug, for the Asian and African markets.
      Published 2024.02.02

      ?? : KBR(https://www.koreabiomed.com)
      👍️ 1
      Monksdream Monksdream 9 months ago
      ASRT new 52 week low
      🌈 1 🍆 1 👎️ 1 🩳 1
      dcaf7 dcaf7 11 months ago
      What is interesting, Coherus said their injector is more patient friendly than what is used in Onpro. So, it looks like a competition of injectors now. Is it possible to win Neulasta market by introducing a better injector? Unexpected twist.
      👍️ 1
      ATLcitizen ATLcitizen 11 months ago
      Good question, dcaf7!
      👍️0
      dcaf7 dcaf7 11 months ago
      Shares of Coherus BioSciences (NASDAQ:CHRS) surged 36.4% after the FDA had approved an on-body injector version of the biosimilar – Udenyca for post-chemotherapy treatment Neulasta.
      https://seekingalpha.com/news/4050413-biggest-stock-movers-today-coherus-biosciences-bit-digital
      It will make more difficult for Rolvedon to compete. Why Spectrum or Assertio didn't start on-body injector program in addition to same day dosing?
      👍️0
      dcaf7 dcaf7 11 months ago
      Hi ATLcitizen! Good to see you here. I think physicians view Ryzneuta the same way as Rolvedon. No clear differentiation from Neulasta. Assertio should work on same day dosing. As for Poziotinib, I don't know. I don't see any new trials with Pozi but I see several drug candidates in development that are less toxic. I found interesting document describing what exactly Spectrum did to be acquired. It looks like Hanmi was considering to buy Spectrum.
      https://www.sec.gov/Archives/edgar/data/1808665/000110465923071264/tm2315184-6_s4a.htm
      This acquisition story is described on pp71-82 step by step. Board was interested to sell the company when TR became a CEO. "Following the appointment of Thomas J. Riga as Spectrum’s President and Chief Executive Officer effective January 1, 2022, the Spectrum board of directors engaged in discussions regarding potential strategic alternatives at each of its regularly scheduled meetings and authorized Mr. Riga and the Spectrum management team to explore potential strategic alternatives".
      👍️ 1
      ATLcitizen ATLcitizen 11 months ago
      What a shocker. I thought Pozi was dead. What do you think Hanmi is trying to do- get approval for 3rd line treatment? What about the whole dosing and side effects problem that FDA issued a CRL for--is Hanmi addressing that as far as you know? Do you know if MDA is still interested in investigating Pozi or have moved on? TIA.
      👍️0
      ATLcitizen ATLcitizen 11 months ago
      Hi dcaf7! Found you again! What do you think of Ryzneuta?
      👍️0
      dcaf7 dcaf7 11 months ago
      Ryzneuta was approved 3 weeks ago. Second "novel" long-acting G-CSF. Acrotech is going to market it in the US. It is same company that markets five Spectrum drugs.
      https://acrotechbiopharma.com/wp-content/uploads/2023/11/Evive-and-Acrotech-Announce-FDA-Approval-of-Ryzneuta.pdf
      👍️ 1
      dcaf7 dcaf7 11 months ago
      On Hanmi. Brokerages raise stock price targets for Korean traditional pharma citing licensing deals, export gains.
      Daishin Securities set the target prices for Hanmi Pharm and Yuhan Corp. from the current 315,500 won and 63,300 won to 420,000 won and 92,000 won, respectively. Hanmi has strengths in the continued steady profit growth through the sales of key products like Rosuzet, Amozaltan family, and Rolvedon.
      👍️0
      dcaf7 dcaf7 1 year ago
      Hanmi is ready to conduct a Phase 4 study "Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (NEUTHREE)". Title is misleading since they are using Eflapegrastim (Rolvedon), not Pegfilgrastim (Neulasta). You can see it in official title, "Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy". Here is a rationale for this study, "It is known that patients who experience neutropenia after the first round of chemotherapy are more likely to experience it again in subsequent rounds. The investigators aimed to see whether changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy for patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round can reduce the incidence of neutropenia".
      https://classic.clinicaltrials.gov/ct2/show/NCT05949333?term=eflapegrastim&draw=2&rank=2
      👍️ 1
      Johnny R Johnny R 1 year ago
      very disappointing earnings release . . . . and the insiders all sold their stock to cover taxes on their options . . . . sure, whatever you say
      👍️0
      Johnny R Johnny R 1 year ago
      wow that has been kept quiet. I presume it will be discussed in the quarterly earnings call
      👍️0
      dcaf7 dcaf7 1 year ago
      Hanmi posted 3dQ results. In their presentation you can find, "pan HER - preparing for global phase 3 trial" with Assertio as a partner.
      http://www.hanmi.co.kr/upfile/ces/information/INFORMATION_PRESENTATIONS/90166507/127540fe-3519-4cb1-95bb-0ce29cb172ee.pdf
      👍️0
      dcaf7 dcaf7 1 year ago
      From VA Formulary Advisor.
      Projected Place in Therapy/Conclusions
      • In 2 phase III clinical trials in patients with early breast cancer receiving myelosuppressive chemotherapy for 4
      cycles in the adjuvant setting, eflapegrastim was non-inferior to pegfilgrastim in reducing the duration of severe
      neutropenia during cycle 1 (primary endpoint) and during cycles 2-4 (secondary endpoint). Pooled rates of febrile
      neutropenia for this chemotherapy combination without G-CSF prophylaxis are 29.1%.
      • Safety during the clinical trial (adverse reactions in ≥20%) was similar between eflapegrastim and pegfilgrastim
      despite the fact that eflapegrastim provides a lower dose of G-CSF compared to pegfilgrastim. The package
      labeling for both products contains the same contraindication and Warnings and Precautions.
      • There is no clear place in therapy for eflapegrastim instead of pegfilgrastim.
      https://www.va.gov/formularyadvisor/DOC/466
      👍️0
      dcaf7 dcaf7 1 year ago
      Ha ha. Good job. Posted by Defense World Staff on Aug 25th, 2023. Equities research analysts at StockNews.com began coverage on shares of Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Free Report) in a note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
      👍️0
      dcaf7 dcaf7 1 year ago
      Rolvedon vs biosimilars cost.
      The final 2 articles highlighted in this issue of the Medical Letter address the question of cost. The first notes the recent approval of the new bone marrow stimulatory agent eflapegrastim-xnst (Rolvedon) for the prevention of chemotherapy-induced febrile neutropenia. The agent was FDA approved based on the results of 2 randomized trials in which it demonstrated noninferiority in one trial and possible superiority in the other trial vs pegfilgrastim (Neulasta).

      Although there should always be interest in discovering novel, increasingly effective, less toxic approaches to supportive care measures in cancer management, the question here is the value of such agents vs less expensive biosimilar agents employed for this purpose. One dose of eflapegrastim is said to cost $4500 compared with pegfilgrastim biosimilar costing approximately $2500. This sum is not insignificant considering the common use of bone marrow stimulatory agents by oncology practices and health care systems, as well as the financial impact on third-party payers or as increasingly mandated insurance co-pay for individual patients.
      https://www.onclive.com/view/unresolved-issues-in-antineoplastic-drug-therapy-is-it-finally-time-to-address-
      👍️ 2
      rado rado 2 years ago
      A few quotes from the call from Dan Peisert

      "We believe we can certainly accelerate the path to profitability, and possibly accelerate the trajectory to a broader reach than what the in-person team has been able to do to date to drive awareness to physicians as well as to purchasing managers."

      "... should enhance our access to the capital markets at a lower cost of capital than either company had on a standalone basis and accelerate our future M&A strategies so we can leverage both our platforms with complementary assets..."

      "...but the synergies will come largely from the contracting and the access teams that will be a tremendous benefit to rest of the Assertio portfolio"

      Dan Peisert also noted that this accelerate their plans and be highly accretive in 2024 and that this is a blockbuster product. There was some mention of 600+ clinics that Spectrum had access to whereas ASRT had access to 2000+ clinics. So the Spectrum product will get advertised more broadly than before, ASRT will probably get access to new clinics and relationships with their non-contact platform.
      👍️0
      rado rado 2 years ago
      The ASRT purchase conference call
      https://events.q4inc.com/attendee/994427686/guest?t=1682444171300
      👍️0
      1hot toddy 1hot toddy 2 years ago
      WOOOOOOOOOOW 2-10K BUYS, ONE 5K BUYS. SMART MONEY BUYING NOT SELLING $$$$$$$$$$
      👍️0
      saigai saigai 2 years ago
      well now..seems like this is the ground floor..saw it a while back and forgot about it so i could have gotten in earlier but im happy.. this is a real equity building event they will leverage some very important assets to shoot the moon.. the best part is the cash position and cfp of many milions a year.. a cash cow..,,enjoy while we can
      👍️0
      saigai saigai 2 years ago
      i dont want to see the 5 dollar space anymore i want 50 but not today because i am doubling up tomorrow.. this is the one that gets me back in the game just need to be patient
      👍️0
      1hot toddy 1hot toddy 2 years ago
      221000 SHARE BUY ON THE CLOSE $$$$$$$$$$$$$$$$ OVER MIL $ BUY
      👍️0
      saigai saigai 2 years ago
      shorts having a field day
      👍️0
      Alan Brown Alan Brown 2 years ago
      Going up ~
      👍️0
      crawford2012 crawford2012 2 years ago
      $Assertio Holdings Inc This is a very smart move by the company, here is why and what it does. In short, buy the friking dip.
      These transactions?? reduce our overall debt by $30M, or 42.9%, while consuming only $10.5M in cash (and issue ~$7M shares). In addition, the transactions will ??save the company $2M in annual interest payments, reduce the potential dilution from the exchanged convertible notes by 4.6%, and will be accretive to our diluted EPS by $0.02 in 2023," CEO Dan Peisert commented.

      ??????????????????????????????
      👍️0
      saigai saigai 2 years ago
      wish i had some powder to put here
      👍️0
      yankee2 yankee2 3 years ago
      ASRT $3.00 Looking good so far

      https://www.barchart.com/stocks/quotes/ASRT/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=ASRT&grid=1&height=500&studyheight=100


      glta
      👍️0
      TrendTrade2016 TrendTrade2016 3 years ago
      ASRT picking up speed now!!!
      👍️0
      TrendTrade2016 TrendTrade2016 3 years ago
      ASRT ...rock star biotech!!!
      👍️0
      TrendTrade2016 TrendTrade2016 3 years ago
      ASRT the trend is your friend
      👍️0
      TrendTrade2016 TrendTrade2016 3 years ago
      ASRT wowza...trading to perfection!
      👍️0
      TrendTrade2016 TrendTrade2016 3 years ago
      ASTR ready to go
      👍️0

      Your Recent History

      NASDAQ
      ASRT
      Assertio
      BIT
      P1UD45
      NLBNPIT1UD45 20991231 10...
      Delayed Upgrade Clock